With years of experience in bispecific antibody (BsAb) engineering, Creative Biolabs provides custom BsAbs against various cancers. Our experts can design and perform different BsAbs construction according to the antigens you are interested in, for both scientific and clinical purposes.
Figure: Mechanism of action of catumaxomab (Nat Biotechnol, 2010)
BsAbs combine the advantages of both classical monoclonal antibodies and bispecific molecules to achieve an increased antitumor activity. There have been many BsAbs in clinical development such as catumaxomab (Removab®), blinatumomab (Blincyto®), ertumaxomab, solitomab, etc., the first two of which have received market approval. According to your individual requirements, our antibody engineering platform can also provide all of the five classes of BsAbs with different formats. We are experienced in generating BsAbs based on advanced techniques such as BiTE, CrossMab, dock-and-lock, all of which can be used to treat diverse cancers, such as advanced solid tumors, malignant ascites, ALL, neuroblastoma and osteosarcoma. Typically, they can induce anti-tumor responses through various mechanisms: retargeting of T/NK cells to tumor, Fc mediated effector functions, blockage of two antigens (such as pro-angiogenic factors), etc.
Creative Biolabs has been devoted to oncotherapy research for many years. Leveraging advanced immunotherapy technology and antibody engineering platforms, our scientists have developed diverse bispecific antibodies against cancers.